Continuous Enteral Rehydration by Nasogastric Tube With ORS in Children With Acute Gastroenteritis: Evaluation of Professional Practices Before and After Protocol Change
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 88
- 试验地点
- 1
- 主要终点
- Number of nasogastric tube after changing gastroenteritis rehydration protocol
研究概览
简要总结
When oral rehydration is impossible, enteral rehydration via the nasogastric route has been the recommended method of rehydration since 2008 by ESPGHAN ( European Society for Paediatric Gastroenterology Hepatology and Nutrition ), for children with acute gastroenteritis. However, these recommendations are rarely followed in France. These recommendations were not applied in the Children's Emergency Department of BREST University Hospital. The investigators changed the protocol and shared it with the caregivers of the emergency unit. The investigators studied the impact of this change of protocol
详细描述
The main purpose was to assess the proportion of children rehydrated by nasogastric tube(NG) after protocol change. Secondary outcomes were to assess hospital length of stay and sides effects.
It is a retro and prospective study. The first phase took place from June to September 2018 and the second from June to September 2019. Any child presenting to pediatric emergencies for acute gastroenteritis requiring nonoral rehydration was included.
研究设计
- 研究类型
- Observational
- 观察模型
- Other
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 1 Day 至 15 Years（Child）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Any child presenting to pediatric emergencies for acute gastroenteritis requiring nonoral rehydration was included
排除标准
- •acute gastroenteritis on return from tropical countries
- •child with endocrine system diseases requiring parenteral rehydration
- •history of chronic pathology requiring enteral feeding
结局指标
主要结局
Number of nasogastric tube after changing gastroenteritis rehydration protocol
时间窗: 4 months
assessed by the number of NG tube and IV in each group
次要结局
- Hospital lenght of stay between each group(4 months)
- Number of Participants With Treatment-Related Adverse Events for each method(4 months)